Literature DB >> 27175260

Altered microenvironmental regulation of CML stem cells.

R Bhatia1.   

Abstract

Keywords:  BM microenvironment; CML stem cells; LSC heterogeneity; TKI resistance

Year:  2014        PMID： 27175260      PMCID： PMC4851285          DOI： 10.1038/leusup.2014.1

Source DB:  PubMed          Journal:  Leuk Suppl        ISSN： 2044-5210


× No keyword cloud information.
  6 in total

1.  Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.

Authors:  Su Chu; Tinisha McDonald; Allen Lin; Sujata Chakraborty; Qin Huang; David S Snyder; Ravi Bhatia
Journal:  Blood       Date:  2011-09-19       Impact factor: 22.113

2.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Authors:  François-Xavier Mahon; Delphine Réa; Joëlle Guilhot; François Guilhot; Françoise Huguet; Franck Nicolini; Laurence Legros; Aude Charbonnier; Agnès Guerci; Bruno Varet; Gabriel Etienne; Josy Reiffers; Philippe Rousselot
Journal:  Lancet Oncol       Date:  2010-10-19       Impact factor: 41.316

3.  Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.

Authors:  Bin Zhang; Min Li; Tinisha McDonald; Tessa L Holyoake; Randall T Moon; Dario Campana; Leonard Shultz; Ravi Bhatia
Journal:  Blood       Date:  2013-01-08       Impact factor: 22.113

4.  Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.

Authors:  Steffen Koschmieder; Berthold Göttgens; Pu Zhang; Junko Iwasaki-Arai; Koichi Akashi; Jeffery L Kutok; Tajhal Dayaram; Kristin Geary; Anthony R Green; Daniel G Tenen; Claudia S Huettner
Journal:  Blood       Date:  2004-08-26       Impact factor: 22.113

5.  Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

Authors:  David M Ross; Susan Branford; John F Seymour; Anthony P Schwarer; Christopher Arthur; David T Yeung; Phuong Dang; Jarrad M Goyne; Cassandra Slader; Robin J Filshie; Anthony K Mills; Junia V Melo; Deborah L White; Andrew P Grigg; Timothy P Hughes
Journal:  Blood       Date:  2013-05-23       Impact factor: 22.113

6.  Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia.

Authors:  Bin Zhang; Yin Wei Ho; Qin Huang; Takahiro Maeda; Allen Lin; Sung-Uk Lee; Alan Hair; Tessa L Holyoake; Claudia Huettner; Ravi Bhatia
Journal:  Cancer Cell       Date:  2012-04-17       Impact factor: 31.743
  6 in total
  1 in total

Review 1.  Chronic myeloid leukemia: reminiscences and dreams.

Authors:  Tariq I Mughal; Jerald P Radich; Michael W Deininger; Jane F Apperley; Timothy P Hughes; Christine J Harrison; Carlo Gambacorti-Passerini; Giuseppe Saglio; Jorge Cortes; George Q Daley
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.